Tag Archives: Mozes Victor Konig

Working with HSBC: Mozes Victor Konig Discusses the Benefits

HSBC has been established for close to two-and-a-half centuries.  Since its founding in 1865 by Scottish-born Thomas Sutherland in Hong Kong, it has taken a simple but sound journey to become the banking corporation it is today.

With the initial idea coming from Sutherland’s belief that local businesses needed “better banking facilities,” Sutherland simultaneously had the bank supporting international trade. 

“That was his genius,” believes Mozes Victor Konig, an investor and supporter of HSBC banking.  “When you understand that both local and global needs have to be met simultaneously, then you’re already half way to success,” he adds.

HSBC had a very fast transition from local to international.  Within a month, a branch was opened in Shanghai and four months later, one in London in an effort to exchange operations in the East as well as train junior bankers.

Today HSBC supports over 40 million customers spanning 64 countries and territories worldwide.

Banking for Small Business Owners

When you start a new business, accessing capital is often the first – and biggest – hurdle.  But there are some tried and tested ways of working this out.  Here, we take a look at some of the steps to follow that can help this.

Mozes Konig – a businessman who some years ago had some problems with Interpol which he then resolved – has worked with many startups and small businesses securing loans.  He has gone through a lot of the obstacles with them and is thus able to advise others on avoiding these pitfalls.

“I think one of the most important things to do – before anything else – is making a clear separation between private and business funds. The way you do this is by creating a brand new business checking account,” Konig said.  “It just makes things simpler and all monies become more easily manageable. You get a far clearer picture on your monthly expenses, incomings and outgoings as well as a clear visual on payment processes.”

The next thing to do is to choose which type of financing will work best for your needs.  There are so many around.  Probably the most popular is a term loan  (whereby you get all the money in the beginning and then pay back with interest over a set time) but that isn’t best for everyone. For example, some of these require a guarantee like some asset.  Sometimes the interest rates are extremely high, especially those with online lenders.  It is however a pretty good option for businesses that are not so new to everything and are just looking to expand, not to get off the ground. Obviously it’s important but always good to remind, read the fine print!

Some other options include: commercial mortgage, unsecured business loan, Small Business Administration (SBAs) loans, invoice factoring and merchant cash advances.

European Investments: Booming Biotech

Biotech is becoming an increasingly popular investment choice. The coronavirus pandemic has actually created more potential in this field. Mozes Victor Konig – a businessman who has made substantial investments in the industry – has seen a significant uptake in the field himself.   He explained:

“What you have to realize is that this industry really needs the capital because invariably such biotechnological firms require a lot of money to even be able to consider approaching the FDA for approval.”

Konig – who had some trouble with Interpol some years ago which he has now put behind him – particularly likes this industry as he describes it as “exciting, innovative and really helpful to potentially thousands of people.”

In Italy we are now witnessing a boom with biotech too.  One example of this is the recent announcement from Sofinnova Partners (life sciences Paris-based VC firm) of its upcoming investments in three startups via its Sofinnova Telethon Fund (Italy’s largest fund solely dedicated to biotechnology). These companies are: AAVantgarde Bio, Alia Therapeutics and Borea Therapeutics all of which are in the process of creating therapies that could really help with rare genetic diseases.

These three seed investments total €6M and are in line with Sofinnova Telethon Fund’s strategy of working with cutting edge Italian scientists and successful entrepreneurs in an effort to create high-end companies in the genetic disease section of biotechnology.

Potential investors, says Konig: don’t bypass the biotech industry; it’s a great way forward for many reasons.